Intranasal administration of a stapled relaxin-3 mimetic has anxiolytic- and antidepressant-like activity in rats.

Subhi MarwariAnders PoulsenNorrapat ShihRajamani LakshminarayananR Manjunatha KiniCharles William JohannesBrian William DymockGavin Stewart Dawe

Published in: British journal of pharmacology (2019)

Our preclinical findings demonstrate that targeting the relaxin-3/RXFP3 receptor system via intranasal delivery of an i,i+7 stapled relaxin-3 mimetic may represent an effective treatment approach for depression, anxiety, and related neuropsychiatric disorders.

Keyphrases

sleep quality
major depressive disorder
depressive symptoms
physical activity
drug delivery
bipolar disorder
smoking cessation